Interleukin-27 signaling promotes immunity against endogenously arising murine tumors
Interleukin-27 (IL-27) is a pleiotropic cytokine but its immunosuppressive effects predominate during many in vivo immunological challenges. Despite this, evidence from tumor cell line transfer models suggested that IL-27 could promote immune responses in the tumor context. However, the role of IL-27 in immunity against tumors that develop in situ and in tumor immunosurveillance remain undefined. In this study, we demonstrate that tumor development and growth are accelerated in IL-27 receptor alpha (Il27ra)-deficient mice. Enhanced tumor growth in both carcinogen-induced fibrosarcoma and oncogene-driven mammary carcinoma was associated with decreased interferon-gamma production by CD4 and CD8 T cells and increased numbers of regulatory T-cells (Treg). This is the first study to show that IL-27 promotes protective immune responses against endogenous tumors, which is critical as the basis for future development of an IL-27 based therapeutic agent.
|Authors||Natividad, K. D.: Junankar, S. R.: Mohd Redzwan, N.: Nair, R.: Wirasinha, R. C.: King, C.: Brink, R.: Swarbrick, A.: Batten, M.:|
|Responsible Garvan Author|
|Publisher Name||PLoS One|
|URL link to publisher's version||http://www.ncbi.nlm.nih.gov/pubmed/23554861|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/11713|